Enrolling by invitationInterventionalPhase 3Last updated Aug 12, 2026

Evaluate the Concordance Between PET Imaging of [18F]-APN-1607 Injection and Postmortem Brain Tissue Tau Pathology in Individuals With HV and MCI or AD.

A Clinicopathological Study to Evaluate the Concordance Between [18F]-APN-1607 Injection PET Imaging and Post-mortem Brain Tau Protein Pathological Changes in Cognitively Normal (HV) Subjects and Patients With AD-derived Mild Cognitive Impairment (MCI) or Alzheimer's Disease (AD) Dementia.

Overview

ClinicalTrials.gov ID: NCT07752784
Lead Sponsor: JYAMS PET Research & Development LimitedINDUSTRY
Brief Summary: To evaluate the diagnostic performance of [18F]-APN-1607 injection PET imaging in detecting uptake patterns consistent with AD neuropathological changes as defined by the National Institute on Aging-Alzheimer's Association (NIA-AA) criteria.

To assess the association between [18F]-APN-1607 injection and Alzheimer's disease (AD)-related tau neurofibrillary pathology (as determined by post-mortem brain tissue histopathology), and detect the uptake pattern corresponding to neurofibrillary tangle (NFT) scores.

To evaluate the safety of [18F]-APN-1607 injection.

Status

Overall Status: Enrolling by invitation
Start Date: Aug 15, 2026Estimated
Primary Completion Date: Apr 30, 2027Estimated
Completion Date: Aug 15, 2027Estimated

Study Record Dates

First Submitted: Jul 29, 2026
First Submitted that Met QC Criteria: Aug 3, 2026
First Posted: Aug 7, 2026Actual
Last Update Submitted that Met QC Criteria: Aug 10, 2026
Last Update Posted: Aug 12, 2026Actual
Last Verified: Aug 2026

NCT07422857Recruiting

Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function

NCT05542953Completed

[18F]APN-1607 PET in Subjects With AD Compared to HC

NCT04141150Unknown status

Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients Compared With Healthy Subjects

NCT05043675Unknown status

Clinical Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients

NCT03545789Completed

Phase 1 Test-retest Evaluation of [18F]MNI-958 PET

NCT03058965Completed

Phase 0 Evaluation of [18F]MNI-958 as a Potential PET Radioligand for Imaging Tau Protein in the Brain